Comparative efficacy and safety of lactulose plus paraffin vs polyethylene glycol in functional constipation: a randomised clinical study.


Journal

United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 1 7 2020
medline: 13 7 2021
entrez: 30 6 2020
Statut: ppublish

Résumé

Few head-to-head comparisons of the different classes of laxatives have been conducted. The objective of this work is to compare the efficacy of lactulose plus paraffin vs polyethylene glycol in the treatment of functional constipation (non-inferiority study). This randomised, parallel-group, multicentre phase 4 study recruited patients with functional constipation diagnosed according to Rome III criteria. Patients received lactulose plus paraffin or polyethylene glycol for 28 days. The primary end point was the change from baseline in the Patient Assessment of Constipation-Symptoms (PAC-SYM) score. A total of 363 patients were randomised to lactulose plus paraffin ( Lactulose plus paraffin may be used interchangeably with polyethylene glycol for the pharmacological treatment of functional constipation.

Sections du résumé

BACKGROUND
Few head-to-head comparisons of the different classes of laxatives have been conducted.
OBJECTIVE
The objective of this work is to compare the efficacy of lactulose plus paraffin vs polyethylene glycol in the treatment of functional constipation (non-inferiority study).
METHODS
This randomised, parallel-group, multicentre phase 4 study recruited patients with functional constipation diagnosed according to Rome III criteria. Patients received lactulose plus paraffin or polyethylene glycol for 28 days. The primary end point was the change from baseline in the Patient Assessment of Constipation-Symptoms (PAC-SYM) score.
RESULTS
A total of 363 patients were randomised to lactulose plus paraffin (
CONCLUSION
Lactulose plus paraffin may be used interchangeably with polyethylene glycol for the pharmacological treatment of functional constipation.

Identifiants

pubmed: 32594884
doi: 10.1177/2050640620937913
pmc: PMC7707874
doi:

Substances chimiques

Drug Combinations 0
Laxatives 0
Polyethylene Glycols 3WJQ0SDW1A
Lactulose 4618-18-2
Paraffin 8002-74-2

Types de publication

Clinical Trial, Phase IV Equivalence Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

923-932

Références

Neurogastroenterol Motil. 2010 Sep;22(9):991-8, e255
pubmed: 20529205
Scand J Gastroenterol. 1999 Sep;34(9):870-7
pubmed: 10522604
Aliment Pharmacol Ther. 2009 Feb 1;29(3):315-28
pubmed: 19035970
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1103-1111
pubmed: 28983926
World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):334-42
pubmed: 27158549
Therap Adv Gastroenterol. 2012 Jul;5(4):233-47
pubmed: 22778789
JAMA. 2012 Dec 26;308(24):2594-604
pubmed: 23268518
Neurogastroenterol Motil. 2012 Nov;24(11):999-e541
pubmed: 22882724
J Clin Gastroenterol. 2011 Jul;45(6):483-7
pubmed: 21666546
Neurogastroenterol Motil. 2014 Jan;26(1):21-7
pubmed: 24106924
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
Gastroenterol Clin Biol. 2007 Feb;31(2):125-35
pubmed: 17347618
Health Technol Assess. 2010 Nov;14(52):1-251
pubmed: 21059322
Aliment Pharmacol Ther. 2013 May;37(9):876-86
pubmed: 23480216
Scand J Gastroenterol. 2005 May;40(5):540-51
pubmed: 16036506
Clin Med Insights Gastroenterol. 2017 Aug 31;11:1179552217729343
pubmed: 28894394
Gut. 2017 Sep;66(9):1611-1622
pubmed: 27287486
Am J Gastroenterol. 2011 Sep;106(9):1582-91; quiz 1581, 1592
pubmed: 21606976
Neurogastroenterol Motil. 2011 Aug;23(8):697-710
pubmed: 21605282
Aliment Pharmacol Ther. 2014 Feb;39(3):239-53
pubmed: 24308797
J Nutr Health Aging. 2017;21(4):429-439
pubmed: 28346570
Can J Gastroenterol. 2011 Oct;25 Suppl B:29B-35B
pubmed: 22114755
Cochrane Database Syst Rev. 2010 Jul 07;(7):CD007570
pubmed: 20614462
Eur J Gastroenterol Hepatol. 2016 May;28(5):525-31
pubmed: 26862934
Aliment Pharmacol Ther. 2007 Jul 15;26(2):227-36
pubmed: 17593068
Gastroenterology. 2013 Jan;144(1):218-38
pubmed: 23261065

Auteurs

T Piche (T)

University of Nice Sophia Antipolis, Nice, France.
Unit of Medical Oncology, Department of Gastroenterology, CHU Nice, Nice, France.

M Dapoigny (M)

Médecine Digestive CHU Clermont-Ferrand, France.
Université Clermont Auvergne, Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH